Polman C - Search Results

1

Treatment with laquinimod reduces development of active MRI lesions in relapsing MS.

Polman C, Barkhof F, Sandberg-Wollheim M, Linde A, Nordle O, Nederman T; Laquinimod in Relapsing MS Study Group. Polman C, et al. Neurology. 2005 Mar 22;64(6):987-91. doi: 10.1212/01.WNL.0000154520.48391.69. Neurology. 2005. PMID: 15781813 Clinical Trial.

2

Correlating MRI and clinical disease activity in multiple sclerosis: relevance of hypointense lesions on short-TR/short-TE (T1-weighted) spin-echo images.

van Walderveen MA, Barkhof F, Hommes OR, Polman CH, Tobi H, Frequin ST, Valk J. van Walderveen MA, et al. Among authors: polman ch. Neurology. 1995 Sep;45(9):1684-90. doi: 10.1212/wnl.45.9.1684. Neurology. 1995. PMID: 7675227

3

Accumulation of hypointense lesions ("black holes") on T1 spin-echo MRI correlates with disease progression in multiple sclerosis.

Truyen L, van Waesberghe JH, van Walderveen MA, van Oosten BW, Polman CH, Hommes OR, Adèr HJ, Barkhof F. Truyen L, et al. Among authors: polman ch. Neurology. 1996 Dec;47(6):1469-76. doi: 10.1212/wnl.47.6.1469. Neurology. 1996. PMID: 8960729

4

Increased MRI activity and immune activation in two multiple sclerosis patients treated with the monoclonal anti-tumor necrosis factor antibody cA2.

van Oosten BW, Barkhof F, Truyen L, Boringa JB, Bertelsmann FW, von Blomberg BM, Woody JN, Hartung HP, Polman CH. van Oosten BW, et al. Among authors: polman ch. Neurology. 1996 Dec;47(6):1531-4. doi: 10.1212/wnl.47.6.1531. Neurology. 1996. PMID: 8960740

5

Treatment of multiple sclerosis with the monoclonal anti-CD4 antibody cM-T412: results of a randomized, double-blind, placebo-controlled, MR-monitored phase II trial.

van Oosten BW, Lai M, Hodgkinson S, Barkhof F, Miller DH, Moseley IF, Thompson AJ, Rudge P, McDougall A, McLeod JG, Adèr HJ, Polman CH. van Oosten BW, et al. Among authors: polman ch. Neurology. 1997 Aug;49(2):351-7. doi: 10.1212/wnl.49.2.351. Neurology. 1997. PMID: 9270561 Clinical Trial.

6

Functional correlates of callosal atrophy in relapsing-remitting multiple sclerosis patients. A preliminary MRI study.

Barkhof FJ, Elton M, Lindeboom J, Tas MW, Schmidt WF, Hommes OR, Polman CH, Kok A, Valk J. Barkhof FJ, et al. Among authors: polman ch. J Neurol. 1998 Mar;245(3):153-8. doi: 10.1007/s004150050196. J Neurol. 1998. PMID: 9553845

7

Concurrent validity of the MS Functional Composite using MRI as a biological disease marker.

Kalkers NF, Bergers L, de Groot V, Lazeron RH, van Walderveen MA, Uitdehaag BM, Polman CH, Barkhof F. Kalkers NF, et al. Among authors: polman ch. Neurology. 2001 Jan 23;56(2):215-9. doi: 10.1212/wnl.56.2.215. Neurology. 2001. PMID: 11160958

8

TNFalpha production by CD4(+) T cells predicts long-term increase in lesion load on MRI in MS.

Killestein J, Kalkers NF, Meilof JF, Barkhof F, van Lier RA, Polman CH. Killestein J, et al. Among authors: polman ch. Neurology. 2001 Sep 25;57(6):1129-31. doi: 10.1212/wnl.57.6.1129. Neurology. 2001. PMID: 11571353

9

Optimizing the association between disability and biological markers in MS.

Kalkers NF, Bergers E, Castelijns JA, van Walderveen MA, Bot JC, Adèr HJ, Polman CH, Barkhof F. Kalkers NF, et al. Among authors: polman ch. Neurology. 2001 Oct 9;57(7):1253-8. doi: 10.1212/wnl.57.7.1253. Neurology. 2001. PMID: 11591845

10

Seasonal variation in immune measurements and MRI markers of disease activity in MS.

Killestein J, Rep MH, Meilof JF, Adèr HJ, Uitdehaag BM, Barkhof F, van Lier RA, Polman CH. Killestein J, et al. Among authors: polman ch. Neurology. 2002 Apr 9;58(7):1077-80. doi: 10.1212/wnl.58.7.1077. Neurology. 2002. PMID: 11940696

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

568 results

Search Page

Filters